These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 7770603

  • 1. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
    Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
    Nomoto M, Jenner P, Marsden CD.
    Neurosci Lett; 1988 Nov 11; 93(2-3):275-80. PubMed ID: 2907373
    [Abstract] [Full Text] [Related]

  • 6. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Biochem Pharmacol; 1995 May 11; 49(9):1185-93. PubMed ID: 7763300
    [Abstract] [Full Text] [Related]

  • 7. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R, Bédard PJ, Britton DR, Shiosaki K.
    Neurology; 1997 Aug 11; 49(2):421-6. PubMed ID: 9270571
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
    Hu XT, Brooderson RJ, White FJ.
    Neuroscience; 1992 Sep 11; 50(1):137-47. PubMed ID: 1357592
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Neuropharmacology; 1994 May 11; 33(5):647-55. PubMed ID: 7936100
    [Abstract] [Full Text] [Related]

  • 12. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M, Grondin R, Goulet M, Bédard PJ, Di Paolo T.
    J Neurochem; 1999 Feb 11; 72(2):682-92. PubMed ID: 9930741
    [Abstract] [Full Text] [Related]

  • 13. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.
    J Pharmacol Exp Ther; 1996 Jan 11; 276(1):150-60. PubMed ID: 8558425
    [Abstract] [Full Text] [Related]

  • 14. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
    Elliott PJ, Walsh DM, Close SP.
    Neurosci Lett; 1992 Aug 03; 142(1):1-4. PubMed ID: 1357609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan 03; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 17. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
    Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC.
    Mov Disord; 1994 Nov 03; 9(6):664-72. PubMed ID: 7845408
    [Abstract] [Full Text] [Related]

  • 18. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr 03; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 19. The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
    Andringa G, Vermeulen RJ, Drukarch B, Renier WO, Stoof JC, Cools AR.
    Behav Pharmacol; 1999 Mar 03; 10(2):163-73. PubMed ID: 10780829
    [Abstract] [Full Text] [Related]

  • 20. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats.
    Arnt J, Bøgesø KP, Hyttel J, Meier E.
    Pharmacol Toxicol; 1988 Mar 03; 62(3):121-30. PubMed ID: 3259694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.